Recent progress of manipulating pluripotent stem cells expands possibilities of regenerative medicine and opens novel transplantation medicine. However, in many cases of these medicines, the relationship between therapeutic cells and recipients would be allogeneic. In this context, we proposed new concept of immune regulation therapy in new-age medicine using pluripotent stem cells. In our concept, not only grafts but also immune regulating cells are generated from pluripotent stem cells by exertion of its pluripotency. We have recently developed immune suppressive macrophage-like cells from pluripotent stem cells. These cells suppressed allo-antigen stimulated T cell proliferation in an iNOS dependent manner. Furthermore, these immune suppressive macrophage-like cells derived from pluripotent stem cells prolonged survival of grafts derived from same pluripotent stem cells in allogeneic recipients. Thus, series of our study proved the efficacy of our new immune regulating strategy in the age of regenerative medicine which utilize pluripotent stem cells as a therapeutic cell source.
Introduction
Cell transplantation using pluripotent stem cells as a source has been developed remarkably in recent years.
It is still difficult to make well-structured three dimensional organs in vitro from pluripotent stem cells so far, but there are already many reports that succeeded to make many kinds of tissues or functional cells from pluripotent stem cells .
Pluripotent stem cells and transplantation medicine
One of the big advantages using iPS cells is that one could expect an achievement of rejection-free transplantation when using autologous iPS cells. In the iPS cell banking project, original cells were collected from donors who bear homogeneous HLA allele to reduce immunological rejection. However, the immunological concerns still remain because many kinds of proteins in allogeneic cells can be possible antigens. In these days, there are many superior immune suppressive drugs against immune rejection 3) .
So, it is common to use these drugs to avoid and reduce the allogeneic rejection. But long-term use of such drugs sometimes causes severe side effects, e.g., development of a malignant neoplasm and opportunistic infection 4) . In this context, immune suppressive therapies without the use of immunosuppressants are strongly expected.
Novel immune regulating strategy for new-age transplantation medicine using pluripotent stem cells
Pluripotent stem cells, including ES cells 5, 6) and iPS cells 7, 8) , have a potential to differentiate into many kinds of cell-types. Immune cells, including immune regulatory cells, are one of them. So, such immune regulatory cells have a possibility to suppress immune rejection of allogeneic grafts.
We have proposed a new immune regulation strategy in the age of regenerative medicine using pluripotent stem cells 9, 10) (Fig. 1A) . In this strategy, pluripotent stem cells differentiate into grafts as well as immune regulatory cells.
On the occasion of allogeneic transplantation, treatment with the immune regulatory cells may reduce the risk of immune rejection and prolong the graft survival.
To realize our concept, a mouse transplantation model was developed in which both grafts and immune regulatory cells were derived from pluripotent stem cells (Fig. 2) 11) , which were transplanted as grafts, and also into immune regulatory macrophage-like cells 9, 10) . . Gene expression correlated with T cell suppression was higher in ES-SCs than ES-DCs 9) .
On the other hand, genes related to T cell stimulation, such as antigen presenting molecules were expressed relatively higher in ES-DCs than in ES-SCs 9) . These series of results generally suggested that ES-and iPS-SCs might act as immune suppressive cells. 
Macrophage-like immune suppressive cells suppress alloantigen-activated T cell proliferation
Since T cells play important roles in graft rejection in allogeneic transplantation 14) , its regulation is quite important for graft survival. Therefore, we tested immune suppressive function of ES-and iPS-SCs against allo-antigen stimulated T cell proliferation. We prepared dendritic cells as antigen presenting cells from bone marrow of allogeneic mice.
T cells efficiently proliferated when co-cultured with the allogeneic dendritic cells. However, in addition of ESor iPS-SCs into the co-culture, T cell proliferation was significantly inhibited 9, 10) . Further analysis revealed that this inhibitory function of ES-and iPS-SCs was supported in an iNOS dependent manner 9, 10) .
Pluripotent stem cells-derived immune suppressive cells prolonged survival of allogeneic grafts
Furthermore, immune suppressive function of ES-and iPS-SCs was tested in vivo allogeneic transplantation model (Fig. 2) . To perform this, we prepared cardiomyocytes or embryoid bodies as grafts from the same ES-or iPS-cells with ES-or iPS-SCs' source.
In in vivo model, irradiated ES-SCs were administered
into allogeneic recipients before the graft transplantation.
Compared with mice without the ES-SCs treatment, it significantly prolonged the graft survival 9) . Importantly, ex vivo analysis revealed that formation of donor-type specific immune suppression in recipients was observed 9) . Briefly, .
Pathological analysis showed that reduced T cell infiltration in the grafts was observed in ES-SCs treated mice 9) .
Interestingly, the administered ES-SCs were not observed in the transplanted site 9) . This result suggested that immune suppressive function of ES-SCs was exerted systemically rather than locally. Similar results were generally obtained when iPS-SCs were used as immune suppressive cells in in vivo experiments 10) .
Administration of the immune suppressive cells into allogeneic recipients suppressed anti-allo antigen antibody production in vivo
We further analyzed immune suppressive function of these immune suppressive cells in vivo 10) . We believe that the strategy generating immune regulatory cells from pluripotent stem cells would be more important than expected so far.
